Trial Profile
A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TYPHER
- 06 Jun 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified June 2016).
- 16 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClnicalTrials.gov record.
- 19 Sep 2014 New trial record